10-K: Yield10 Bioscience Reports Full Year 2023 Results, Adjusts Biofuel Strategy

Yield10 Bioscience shifts its biofuel strategy to focus on R&D services and licensing, while advancing its omega-3 Camelina program towards commercialization.

Summary

• Yield10 Bioscience is an agricultural bioscience company focused on commercializing sustainable products using Camelina sativa as a platform crop.
• The company is pursuing two main products: omega-3 oils for aquaculture and low-carbon intensity feedstock oils for biofuels.
• In early 2024, Yield10 adjusted its biofuel strategy to focus on providing research and development services to third parties, aiming to generate service and licensing revenues.
• This decision was influenced by the current excess supply of soybean oil for biofuels and the company's financial challenges as a small-cap pre-revenue entity.
• Yield10 has developed proprietary, engineered spring and winter Camelina varieties, including herbicide-tolerant (HT) and stacked HT traits.
• The company signed its first non-exclusive global, commercial license with Vision Bioenergy Oilseeds for certain Camelina lines and herbicide tolerance traits.
• Yield10 is also advancing its omega-3 Camelina program, having received regulatory approval from USDA-APHIS for two engineered lines producing EPA and EPA+DHA omega-3 oils.
• The company plans to continue seed scale-up of EPA8 Omega-3 Camelina, targeting 2026 for the first commercial-scale production of the oil.
• Yield10 is building an intellectual property portfolio around its crop technologies and traits, with 18 patent families, including 20 issued patents and 30 pending applications.
• The company is targeting a growing omega-3 deficit estimated to be between 300,000 and 600,000 tons of fish oil equivalent per year.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in technology and market opportunities, the company's financial situation and going concern status raise significant concerns. The shift in biofuel strategy also indicates challenges in that market segment.

Positives

• Yield10 has successfully developed and received regulatory approval for herbicide-tolerant and stacked herbicide-tolerant Camelina varieties.
• The company is making progress in developing a sustainable, plant-based source of omega-3 oils.
• Yield10 has secured a commercial license for its HT and stacked HT traits, indicating market interest in its technology.
• The company has a strong intellectual property portfolio with numerous patents and applications.
• Yield10 is targeting a large and growing market for omega-3 oils, with a significant supply deficit projected.
• The company has a clear path to commercialization for its omega-3 products, with a target date for first commercial-scale production.

Negatives

• Yield10 has a history of net losses and an accumulated deficit of $414.152 million as of December 31, 2023.
• The company's cash resources are expected to fund operations only into the second quarter of 2024, raising substantial doubt about its ability to continue as a going concern.
• Yield10 has adjusted its biofuel strategy due to excess supply of soybean oil and financial challenges.
• The company is dependent on securing additional funding to finance its operations.
• The crop science product development cycle is lengthy and uncertain, and there is no guarantee of commercial success.
• The company faces intense competition in the market for traits and seeds.

Risks

• Yield10's limited cash resources and uncertainty about securing additional funding pose a significant risk to its operations.
• The company's seed products and crop science technologies are at an early stage of development, with no guarantee of commercialization.
• The company may not be able to comply with the continued listing standards of The Nasdaq Capital Market.
• Global geopolitical conflicts may adversely affect the company's business, financial condition, or results of operations.
• The crop science product development cycle is lengthy and uncertain, and the company's progress depends on attracting third-party investment.
• The company's estimates of market opportunity and forecasts of market growth may prove to be inaccurate.
• Adverse weather conditions, natural disasters, crop disease, pests, and other natural conditions can impose significant costs and losses on the business.
• The company relies on third parties to conduct field trials and maintain regulatory files, and any performance issues by these parties may impact the company's ability to commercialize products.
• The company's patent protection for its technologies is both important and uncertain.
• Third parties may claim that the company infringes their intellectual property, leading to litigation or licensing expenses.

Future Outlook

Yield10 plans to focus on developing and commercializing its omega-3 Camelina products, targeting the aquaculture market, while seeking partnerships for its biofuel technologies. The company expects to continue its development work with spring E3902 stack HT Camelina and winter stack HT Camelina during early 2024. The company is targeting 2026 for the first commercial-scale production of EPA8 Omega-3 Camelina oil.

Management Comments

• Management is urgently evaluating and pursuing different strategies to obtain the required funding for our operations in the near term.
• Management believes that the stacked HT trait package will be an important enabler for large acre adoption and particularly for winter Camelina varieties.
• Management believes that Camelina omega-3 oil production at scale can reduce supply and price volatility in aquafeed and farmed salmon production.

Industry Context

The announcement reflects a broader industry trend towards sustainable and alternative sources of omega-3 oils and biofuels. The shift in strategy towards R&D services and licensing for biofuels is a response to the current market conditions and financial constraints faced by smaller companies in the sector. The focus on omega-3 oils aligns with the growing demand for sustainable alternatives to fish oil in aquaculture and human nutrition.

Comparison to Industry Standards

• Yield10's focus on Camelina as a platform crop is similar to other companies exploring alternative oilseed crops for biofuels and specialty oils, such as Nuseed with carinata and CoverCress Inc. with pennycress.
• The development of herbicide-tolerant traits in Camelina is a common strategy in the agricultural biotechnology industry to improve crop adoption and performance, similar to the development of herbicide-tolerant canola and soybean.
• The company's approach to omega-3 production through genetic engineering of oilseed crops is comparable to other companies like Nuseed and BASF, who have developed omega-3 producing canola varieties.
• Yield10's focus on a closed-loop production system for omega-3 oils is similar to other companies aiming to control the supply chain and ensure product quality.
• The company's shift towards R&D services and licensing for biofuels is a common strategy for smaller companies to leverage their technology without the need for large-scale capital investment, similar to other companies in the agricultural biotechnology sector.

Management Changes

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial challenges and need for additional funding.
• Employees are impacted by temporary salary adjustments and potential job insecurity due to the company's financial situation.
• Customers and partners may be affected by the company's shift in strategy and potential delays in product development.
• Suppliers and creditors may face increased risk due to the company's financial instability.

Next Steps

• Yield10 plans to continue seed scale-up of EPA8 Omega-3 Camelina, targeting 2026 for the first commercial-scale production of the oil.
• The company expects to finalize the Exclusive Commercial License with Rothamsted in the second quarter of 2024.
• Yield10 will continue to develop its grower network and shift to a traditional seed sales model for some of its Camelina varieties.
• The company plans to continue executing partnerships and other types of agreements for the development of Camelina technologies used in the production of biofuels.
• The company will continue its focus on developing elite Camelina varieties with herbicide tolerance, disease resistance, higher yield and oil content.

Key Dates

Keywords

Camelina, Omega-3, Biofuels, Herbicide Tolerance, Seed Oil, Aquaculture, EPA, DHA, R&D, Licensing, Crop Science, Biotechnology